6FK Stock Overview

Researches, develops, and produces biochemical reagents for use in medical diagnostics and research worldwide. More details

6FK fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	5/6
Past Performance	2/6
Financial Health	6/6
Dividends	0/6

Rewards

Earnings are forecast to grow 63.49% per year

Became profitable this year

Risk Analysis

Large one-off items impacting financial results

Does not have a meaningful market cap (€601M)

My Notes

Capture your thoughts, links and company narrative

Gentian Diagnostics ASA Competitors

Paul Hartmann

DB:PHH2

€788.5m

MeVis Medical Solutions

XTRA:M3V

€44.4m

PULSION Medical Systems

MUN:PUS

€133.6m

HAEMATO

HMSE:HAEK

€55.4m

Price History & Performance

Summary of share price highs, lows and changes for Gentian Diagnostics
Historical stock prices
Current Share Price	NOK 3.24
52 Week High	NOK 5.05
52 Week Low	NOK 3.00
Beta	0.52
1 Month Change	-6.90%
3 Month Change	-14.74%
1 Year Change	-8.47%
3 Year Change	-53.45%
5 Year Change	n/a
Change since IPO	-31.79%

Recent updates

Shareholder Returns

	6FK	DE Medical Equipment	DE Market
7D	-0.6%	-3.3%	-2.0%
1Y	-8.5%	-8.5%	6.9%

Return vs Industry: 6FK matched the German Medical Equipment industry which returned -8.5% over the past year.

Return vs Market: 6FK underperformed the German Market which returned 6.9% over the past year.

Price Volatility

Is 6FK's price volatile compared to industry and market?
6FK volatility
6FK Average Weekly Movement	5.5%
Medical Equipment Industry Average Movement	6.7%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.3%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 6FK has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: 6FK's weekly volatility (5%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2001	58	Njaal Kind	www.gentian.com

Gentian Diagnostics ASA researches, develops, and produces biochemical reagents for use in medical diagnostics and research worldwide. The company offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Circulating Calprotectin Immunoassay, a turbidimetric immunoassay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a glomerular filtration rate marker for the diagnosis and therapeutic control of renal function; Gentian Retinol-Binding Protein Immunoassay for detection of retinol-binding protein in human serum and plasma; and canine CRP immunoassay test kit, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine C-reactive protein in dog plasma and serum. It also provides SARS-CoV-2 total antibody immunoassay, quantitative antibody test captures the full immune response detecting antibodies targeting the S1-subunit.

Gentian Diagnostics ASA Fundamentals Summary

How do Gentian Diagnostics's earnings and revenue compare to its market cap?
6FK fundamental statistics
Market cap	€50.88m
Earnings (TTM)	€187.81k
Revenue (TTM)	€13.04m

270.9x

P/E Ratio

3.9x

P/S Ratio

Is 6FK overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6FK income statement (TTM)
Revenue	NOK 154.12m
Cost of Revenue	NOK 67.86m
Gross Profit	NOK 86.26m
Other Expenses	NOK 84.04m
Earnings	NOK 2.22m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 12, 2025

Earnings per share (EPS)	0.14
Gross Margin	55.97%
Net Profit Margin	1.44%
Debt/Equity Ratio	0%

How did 6FK perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/23 10:30
End of Day Share Price	2024/12/20 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Gentian Diagnostics ASA is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
David Martinsson	DNB Markets
Geir Holom	DNB Markets